Glucagon-like peptide 1 (GLP1) agonists and nonsteroidal mineralocorticoid receptor antagonists (MRAs) also show promise to slow CKD progression in T2D, but sex-specific responses to MRAs require further examination (29, 30). The gene discussed is GCG; the disease is chronic kidney disease.